Targeting the SAGA and ATAC Transcriptional Coactivator Complexes in MYC-Driven Cancers

Area of Science:

• Epigenetics
• Cancer Biology
• Molecular Oncology

Background:

• Epigenetic regulators, including histone-modifying enzymes, are emerging targets for cancer therapy.
• The GCN5 lysine acetyltransferase (KAT) plays a role in both normal development and oncogenesis, often interacting with MYC.
• MYC transcription factors are challenging to target directly with small molecules.

Purpose of the Study:

• To review the roles of the SAGA and ATAC complexes, which contain GCN5, in embryonic development and cancer.
• To elucidate the functional relationships between SAGA, ATAC, and MYC family members.
• To assess the therapeutic potential of targeting GCN5-containing complexes in cancer.

Main Methods:

• Literature review of studies on GCN5, SAGA, ATAC, and MYC.
• Analysis of the functional interplay between these factors in development and disease.
• Evaluation of existing and potential therapeutic strategies targeting these epigenetic regulators.

Main Results:

• GCN5, as part of SAGA and ATAC complexes, influences MYC-driven functions.
• These complexes are implicated in both embryonic development and cancer progression.
• The acetyltransferase and bromodomain of GCN5 present potential druggable sites for disrupting MYC-driven oncogenesis.

Conclusions:

• GCN5-containing complexes (SAGA and ATAC) are critical in development and cancer.
• Targeting GCN5's enzymatic or binding domains offers a promising strategy to inhibit MYC-driven cancers.
• Further research into SAGA, ATAC, and their interaction with MYC could yield novel cancer therapeutics.